Vigabatrin

Introduction Overview

Generic Name

vigabatrin

Brand Name

Sabril

Dosage Form

Oral tablets and oral powder for solution

Drug Class

Gamma-aminobutyric acid analogs

Pharmacokinetics

Absorption:
Vigabatrin (Sabril) is rapidly and completely absorbed after oral administration, with peak plasma concentrations typically reached within 1 to 2.5 hours. Its bioavailability approaches 100%, making it highly efficient in systemic uptake. The absorption is unaffected by food intake, and therefore the drug can be administered with or without meals. Studies demonstrate that despite rapid absorption, it may take one to two weeks or longer to observe clinical efficacy in infantile spasms and several weeks for reduction of complex partial seizures, suggesting a pharmacodynamic delay related to its mechanism at synaptic GABA levels.

Distribution:
Once absorbed, vigabatrin demonstrates a relatively wide distribution, including penetration into central nervous system (CNS) tissues, which is essential for its anticonvulsant effect. The drug is minimally bound to plasma proteins, usually less than 5%, suggesting a large free fraction available for CNS uptake. The volume of distribution indicates moderate tissue binding and distribution, but specific CNS tissue concentrations are influenced by blood-brain barrier permeability and active transport mechanisms. In pediatric patients, distribution may vary with weight and age, impacting dosing considerations.

Metabolism:
Vigabatrin undergoes minimal hepatic metabolism and is not significantly biotransformed by liver enzymes. It demonstrates high metabolic stability, with its primary activity attributed to the parent compound. This lack of extensive metabolism reduces the risk of drug interactions through cytochrome P450 pathways. The pharmacological action results from irreversible inhibition of gamma-aminobutyric acid transaminase (GABA-T), leading to increased GABA content in the brain. The absence of active metabolites contributes to a more predictable pharmacokinetic profile.

Elimination:
Elimination of vigabatrin occurs predominantly through renal excretion as unchanged drug, with over 80% recovered unchanged in urine. The renal clearance exceeds creatinine clearance, indicating the involvement of active tubular secretion in drug removal. The elimination half-life ranges between 5 to 8 hours, but pharmacodynamic effects persist beyond plasma clearance due to irreversible enzyme inhibition. In patients with renal impairment, dose adjustments are required to prevent accumulation and toxicity. No significant biliary or fecal excretion has been reported.

Overall, vigabatrin's pharmacokinetic profile supports twice-daily dosing regimens. The lack of metabolism and predominant renal clearance minimize hepatic interaction potential but necessitate caution and dose modification in renal disease. Therapeutic drug monitoring is not routinely performed, but careful clinical observation is required due to risks related to cumulative exposure, especially concerning retinal toxicity.

Dosage Forms

Available Dosage Forms:
Sabril is marketed primarily in two oral dosage forms:
- Oral tablets: 500 mg per tablet, intended for adult and pediatric dosing. The tablets are to be taken orally with or without food.
- Oral powder for solution: Each packet contains 500 mg of vigabatrin powder, designed to be dissolved in water only prior to administration. This formulation is particularly suited for infants and young children, facilitating accurate dosing and administration.

Dosages for Adults and Adolescents:
- For refractory complex partial seizures in patients 17 years and older, the recommended initial dose is 1 gram per day, administered as 500 mg orally twice daily. The dose may be titrated upward in weekly increments of 500 mg based on efficacy and tolerability, with a recommended maintenance dose of approximately 3 grams daily (1.5 grams twice daily).
- A maximum dose of 6 grams daily has been studied but offers no additional benefit versus 3 grams and is associated with increased adverse effects.
- For pediatric patients aged 2 to 16 years with refractory complex partial seizures, dosing is weight-based, with titration conducted in weekly increments. Patients over 60 kg may be dosed similarly to adults.

Specific Patient Populations:
- Infantile Spasms (1 month to 2 years): Vigabatrin is used as monotherapy with initial dosing at 50 mg/kg/day (25 mg/kg twice daily), increased every 3 days by 25 mg/kg/day increments up to a maximum of 150 mg/kg/day (75 mg/kg twice daily). Each dose should be freshly prepared just before administration and served at room temperature or colder to preserve stability.
- Renal Impairment: Due to predominant renal elimination, dose adjustments are advised for patients with impaired kidney function to mitigate risk of drug accumulation and toxicity. Specific dosing modifications depend on renal function estimates.
- Ophthalmologic Monitoring: Mandatory visual function monitoring is required before and every 3 months during therapy, and for up to 6 months post-treatment, due to the risk of permanent vision loss.

The variety of dosage forms and titratable dosing regimens facilitate individualized therapy across age groups, with particular attention to safety monitoring and risk-benefit assessment in both pediatric and adult populations.

Mechanism Of Action

Vigabatrin, the active ingredient in Sabril, exerts its anticonvulsant effects primarily through irreversible inhibition of the enzyme gamma-aminobutyric acid transaminase (GABA-T). This enzyme is responsible for the catabolism of GABA, the chief inhibitory neurotransmitter in the central nervous system. By binding covalently and inactivating GABA-T, vigabatrin markedly increases the concentration of GABA within the brain, enhancing inhibitory synaptic transmission.

This augmentation of GABAergic activity leads to reduced neuronal excitability and stabilization of electrical activity in the brain, which is critical in controlling epileptogenic foci responsible for seizures. Unlike other GABA analogs that may mimic GABA or bind GABA receptors directly, vigabatrin's mechanism involves increasing endogenous GABA availability, resulting in prolonged and sustained inhibitory signaling.

At a cellular level, elevated GABA levels enhance the activation of GABA-A and GABA-B receptors distributed throughout the CNS. Enhanced GABA-A receptor-mediated chloride influx leads to hyperpolarization of neurons, decreasing the likelihood of action potential generation. GABA-B receptor activation contributes to inhibitory modulation through G-protein coupled mechanisms affecting potassium and calcium ion channels, further dampening neuronal excitability.

Clinical implications of this mechanism include effective reduction in seizure frequency, particularly in refractory complex partial seizures and infantile spasms. Research has demonstrated that vigabatrin’s irreversible inhibition confers a prolonged pharmacodynamic effect even after plasma clearance, contributing to its dosing schedule. However, the permanent activation of GABAergic pathways is also implicated in adverse effects such as retinal toxicity and vision loss, believed to involve GABA accumulation in retinal cells leading to cellular damage.

Comparatively, vigabatrin's unique mechanism distinguishes it from other anticonvulsants like benzodiazepines and barbiturates, which modulate GABA receptor activity but do not inhibit GABA metabolism. Clinical studies emphasize vigabatrin's role as an adjunctive or second-line agent, especially where other treatments have failed, balancing efficacy with a significant risk profile necessitating careful patient selection and monitoring.

Pharmacological Actions

Irreversible inhibition of gamma-aminobutyric acid transaminase (GABA-T) enzyme leading to increased brain GABA concentrations.
Enhancement of inhibitory neurotransmission via augmentation of GABA-A and GABA-B receptor activities.
Reduction of neuronal excitability and stabilization of electrical activity in epileptogenic brain regions.
Management of refractory complex partial seizures by decreasing seizure frequency and severity.
Effective monotherapy for infantile spasms through modulation of CNS inhibitory pathways.
Minimal hepatic metabolism reducing potential for cytochrome P450 mediated drug interactions.
Renally excreted unchanged, requiring dose adjustment in renal impairment.
Prolonged pharmacodynamic effect due to irreversible enzyme inhibition despite short plasma half-life.
Associated with dose-dependent risk of permanent visual field defects due to retinal toxicity.
Modulates both presynaptic and postsynaptic GABAergic neurotransmission.
Does not exhibit direct GABA receptor agonism but increases endogenous inhibitory neurotransmitter availability.
May cause CNS-related adverse effects such as drowsiness, dizziness, confusion, and behavioral changes.
Potential to cause mood changes and suicidal ideation requiring close clinical monitoring.
Interaction profile is limited but co-administration with other anticonvulsants requires careful oversight.
Therapeutic effects generally manifest over weeks, emphasizing gradual titration for efficacy.

Therapeutic Or Clinical Uses

Adjunctive treatment for refractory complex partial seizures in patients aged 2 years and older who have failed other therapies.
Monotherapy for infantile spasms in pediatric patients from 1 month to 2 years of age, particularly when benefits outweigh risks.
Management of refractory epilepsy where conventional anticonvulsants are insufficient.
Treatment of seizure disorders characterized by focal onset with or without secondary generalization.
Used in specialized cases requiring seizure control with a non-hepatic metabolized agent.
Prescribed when other GABAergic drugs are ineffective or contraindicated in seizure management.
Potential off-label use in certain cases of epilepsy syndromes dependent on specialist evaluation.
Part of a comprehensive seizure control regimen including other anticonvulsants.
Provides an alternative mechanism of action in polytherapy resistant epilepsy.
Utilized in treatment plans requiring long-term seizure suppression with careful ophthalmologic oversight.
Indicated only when potential benefits justify the risk of irreversible vision loss.
Recommended for patients enrolled in Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) programs.
Not recommended as first-line therapy but as a subsequent option in refractory seizure management.
Used in pediatric neurology to manage developmental epileptic encephalopathies presenting with spasms.
Monitored closely in infants for efficacy and adverse neurological or ophthalmological effects.

Side Or Adverse Effects

Permanent vision loss including peripheral visual field defects and retinal toxicity.
Blurred vision, visual disturbances, and other ocular abnormalities noted during treatment.
Drowsiness, dizziness, and somnolence potentially impairing motor function.
Confusion, cognitive impairment, and memory difficulties in some patients.
Mood alterations including agitation, irritability, aggression, anxiety, and depression.
Increased risk of suicidal ideation and behavior requiring monitoring for neuropsychiatric symptoms.
Tremors, unsteady gait, and coordination problems indicating CNS involvement.
Weight gain which may be accompanied by peripheral edema or fluid retention.
Joint pain and musculoskeletal discomfort observed in certain individuals.
Numbness, tingling, or burning sensations suggestive of peripheral neuropathy.
In infants, fussiness, feeding difficulties, ear infections, cough, and respiratory issues.
Severe skin reactions including rash, urticaria, and rare hypersensitivity reactions.
Possible abnormal brain MRI changes in infants, with unclear clinical significance.
Seizure exacerbation or increased seizure frequency in some cases after initiating treatment.
Rare reports of severe allergic reactions including anaphylaxis necessitating emergency care.

Precautions

Mandatory baseline and regular ophthalmologic evaluations every three months during treatment.
Enroll in and comply with the Vigabatrin REMS Program to monitor and mitigate vision risks.
Use only when benefits outweigh risks, especially regarding irreversible visual impairment.
Careful dosing and monitoring in patients with preexisting vision problems or glaucoma.
Dose adjustment or discontinuation may be required if any vision changes are detected.
Avoid abrupt discontinuation to prevent rebound seizures; taper dosage under medical supervision.
Close monitoring of mood and behavior changes due to risk of depression and suicidal ideation.
Use with caution in patients with renal impairment; adjust dosing accordingly to avoid toxicity.
Not recommended for use during breastfeeding due to potential harm to the infant.
Pregnant patients should be counseled about risks; consider enrollment in pregnancy registries.
Avoid driving or operating machinery until individual response and side effects are assessed.
Children require special observation for vision changes, compliance, and adverse effects.
Inform all healthcare providers of use to prevent adverse drug interactions and monitor effects.
Ensure caregivers are educated on signs of vision loss and neuropsychiatric symptoms.
Only use Sabril under supervision of a neurologist or specialist experienced with epilepsy.

Warnings

Use of Sabril can cause permanent and irreversible vision loss, even after discontinuation.
Vision loss may be subtle initially and worsen progressively; patients may not notice early symptoms.
Frequent visual field and retinal examinations are crucial to detect early signs of toxicity.
Some infants may develop abnormal brain MRI findings during treatment, with unclear long-term effects.
Risk of suicidal thoughts and behaviors necessitates close psychiatric monitoring.
Not indicated as first-line therapy due to potential severe adverse effects.
Sudden cessation may lead to increased seizure frequency or severity.
Concomitant use with other CNS depressants may exacerbate sedation and cognitive impairment.
Patients with preexisting anemia or psychiatric disorders require careful evaluation before initiation.
Use in pregnancy may pose risks to fetus; benefits must be carefully weighed.
The drug is only available through a restricted distribution program (REMS) to manage risks.
Do not breastfeed while receiving Sabril, as safety for infants is not established.
Patients should report immediately any vision changes, mood swings, or new symptoms.
High doses beyond recommended levels increase likelihood of adverse effects without added efficacy.
Ongoing patient education is essential to ensure adherence to monitoring and dosing instructions.

Contraindication

Known hypersensitivity or allergy to vigabatrin or any component of the formulation.
Preexisting severe visual field defects or retinal disease that could be worsened by treatment.
Patients unable or unwilling to adhere to vision monitoring requirements under REMS.
Use in breastfeeding mothers due to potential risk of harm to nursing infants.
Severe renal impairment without appropriate dose adjustments due to risk of accumulation.
Patients with a history of psychosis or severe mood disorders without psychiatric management.
Children younger than 1 month of age due to lack of safety and efficacy data.
Use as a sole treatment for refractory partial seizures in patients where alternative treatments are available.
Concurrent use with other investigational agents not approved by regulatory authorities.
Patients with conditions causing increased risk of retinal toxicity (e.g., retinitis pigmentosa).
Individuals with untreated anemia or hematological disorders without appropriate treatment.
Patients with suicidal ideation or recent suicide attempts not receiving adequate psychiatric care.
Known hypersensitivity to excipients present in the tablet or powder formulation.
Patients unable to attend regular ophthalmologic assessments and follow-up visits.
Contraindicated where vision monitoring program requirements cannot be met for any reason.

Drug Interactions

Minimal cytochrome P450 involvement; hence, low potential for interactions via hepatic metabolism.
Possible additive CNS depressant effects when combined with other anticonvulsants or sedatives.
Concomitant use with other GABAergic drugs may potentiate CNS side effects such as sedation.
Interaction with lamotrigine has been observed, warranting monitoring when co-administered.
No significant interactions reported with commonly used antiepileptic drugs like carbamazepine or valproic acid, but clinical vigilance recommended.
Potential interaction with drugs eliminated by renal tubular secretion due to competing pathways.
Use caution with drugs that may exacerbate vision impairment or retinal toxicity.
No significant interference with hormonal contraceptives documented, but patient counseling advised.
The interaction profile with herbal supplements and vitamins has not been extensively studied; caution is advised.
No known significant effects on or by warfarin or anticoagulants, but monitoring standard practice.
Combination with drugs that lower seizure threshold should be avoided or carefully supervised.
No need for dose adjustment of vigabatrin when administered with food or antacids.
Pharmacodynamic interactions with CNS stimulants or depressants may alter seizure control or side effects.
Pregnancy-related drug interactions data are limited; clinical judgment required.
Patients should inform healthcare providers about all concurrent medications including OTC drugs to avoid unforeseen interactions.

Preparations Of The Drug

Sabril 500 mg oral tablets for twice-daily administration, suitable for adults and older children.
Sabril oral powder packets containing 500 mg of vigabatrin per packet intended for reconstitution in water prior to oral administration, preferred for infants and young children.
Reconstituted oral solution to be administered immediately after preparation, at room temperature or cooler, to maintain stability.
Distribution of Sabril restricted under the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program to certified pharmacies and healthcare providers.
Packaging includes comprehensive instructions emphasizing the need for ophthalmologic monitoring and adherence.
Prescriptions require registration and enrollment verification in the REMS program prior to dispensing.
Powder formulation allows accurate dose titration especially crucial in pediatric populations with weight-based dosing.
No parenteral or intravenous formulations currently available.
Tablets should be stored at room temperature, protected from moisture and heat, in original container.
Patient information leaflets mandate warnings regarding the risk of vision loss and requirement for regular eye exams.
Pharmaceutical grade preparations meet stringent quality control to ensure potency and safety in seizure management.
Sensitivity to packaging and storage conditions highlighted to prevent degradation and loss of efficacy.
Reminders provided to patients and caregivers about not sharing medication and adhering strictly to dosing instructions.
Available generically under the name vigabatrin as well as branded formulations.
Prescription only medicine requiring specialist oversight and patient education to optimize therapeutic outcomes.